Welcome to LookChem.com Sign In|Join Free

CAS

  • or
1,3-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1046832-21-6 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1046832-21-6 Structure
  • Basic information

    1. Product Name: 1,3-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester
    2. Synonyms: 1,3-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester;1,3-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole;1,3-DiMethyl-1H-pyrazol-4-ylboronic acid,pinacol ester;1,3-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, 2-(1,3-Dimethyl-1H-pyrazol-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane;1,3-DiMethylpyrazole-4-boronic acid pinacol ester;1,3-diMethyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyrazole;1,3-dimethyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole;1,3-Dimethylpyrazole-4-boronic acid pinacol ester 97%
    3. CAS NO:1046832-21-6
    4. Molecular Formula: C11H19BN2O2
    5. Molecular Weight: 222.09
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1046832-21-6.mol
  • Chemical Properties

    1. Melting Point: 73.0 to 77.0 °C
    2. Boiling Point: 322.3±30.0 °C(Predicted)
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 1.04±0.1 g/cm3(Predicted)
    6. Refractive Index: N/A
    7. Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
    8. Solubility: N/A
    9. PKA: 2.56±0.10(Predicted)
    10. CAS DataBase Reference: 1,3-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester(CAS DataBase Reference)
    11. NIST Chemistry Reference: 1,3-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester(1046832-21-6)
    12. EPA Substance Registry System: 1,3-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester(1046832-21-6)
  • Safety Data

    1. Hazard Codes: Xn
    2. Statements: 22-36/37/38
    3. Safety Statements: 26-36
    4. WGK Germany: 3
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1046832-21-6(Hazardous Substances Data)

1046832-21-6 Usage

Uses

1,3-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester

Check Digit Verification of cas no

The CAS Registry Mumber 1046832-21-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,4,6,8,3 and 2 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1046832-21:
(9*1)+(8*0)+(7*4)+(6*6)+(5*8)+(4*3)+(3*2)+(2*2)+(1*1)=136
136 % 10 = 6
So 1046832-21-6 is a valid CAS Registry Number.

1046832-21-6 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (D5184)  1,3-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole  >97.0%(GC)(T)

  • 1046832-21-6

  • 1g

  • 1,460.00CNY

  • Detail
  • Aldrich

  • (709948)  1,3-Dimethylpyrazole-4-boronic acid pinacol ester  97%

  • 1046832-21-6

  • 709948-1G

  • 2,036.97CNY

  • Detail

1046832-21-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017

1.Identification

1.1 GHS Product identifier

Product name 1,3-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

1.2 Other means of identification

Product number -
Other names 1,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1046832-21-6 SDS

1046832-21-6Relevant articles and documents

Substituted heteroaryl compound and composition and application thereof

-

Paragraph 0590; 0592-0593, (2018/10/19)

The invention provides a substituted heteroaryl compound and a pharmaceutical composition and application thereof. The compound is a compound as shown in formula (I) or the stereisomer, tautomer, nitric oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in formula (I). The pharmaceutical composition containing the compound can regulate the activity ofprotein kinase and especially the activity of Aurora kinase and JAK kinase and is used for preventing, treating and relieving diseases or disorder mediated by protein kinase and especially JAK kinase.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

-

Page/Page column 00343, (2018/10/19)

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY

-

, (2015/06/25)

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE

-

Paragraph 0459; 0460, (2015/05/26)

The present invention embodiments relate to compound of Formula I or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates in certain embodiments to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates in certain embodiments to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates in certain embodiments to a process for manufacturing compounds of Formula I.

Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules

-

Paragraph 0127; 0128, (2013/05/22)

Compositions and methods which modulate diseases and disorders related to transducin β-like protein 1 (TBL1) activity, including but not limited to cancer, inflammation, and bone related diseases.

CONDENSED TRICLYCLIC COMPOUNDS AS INHIBITORS OF HIV REPLICATION

-

Page/Page column 47, (2013/07/05)

Compounds of formula (I) and pharmaceutical compositions thereof: wherein A1 A2 and A3 are each independently selected from the group consisting of N and CR3, wherein R1 is an optionally substituted heterocyclyl or an optionally substituted -(C1-6)alkyl-heterocyclyl, R2 is an optionally substituted aryl or an optionally subsisted heteroaryl, R4 is an optionally substituted aryl, an optionally substituted heterocyclyl or an optionally substituted heteroaryl, useful as an inbitor of HIV replication.

CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

-

Page/Page column 74, (2010/05/14)

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1046832-21-6